Mood Disorders

Learn about screening for postpartum depression and available pharmacological treatments.

Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.

Explore how to manage mood and substance use disorders together, boost engagement, and expand addiction medications.

New data suggest seltorexant may ease insomnia in MDD while limiting weight gain and potentially improving metabolic risk factors.

Phase 3 data show adjunctive seltorexant eases depression and insomnia with lessened weight gain and somnolence.

Sleep and circadian rhythm disruption shape psychiatric symptoms and bipolar mood shifts.

Explore the intersections of bipolar disorder with clinical trials and AI.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

Psychiatrist Gus Alva highlights new depression therapies, neuromodulation, and why screening for bipolar disorder prevents antidepressant harm.

Learn why insomnia and daytime sleepiness signal psychiatric risk, and how screening for apnea, delayed phase, and fatigue sharpens treatment.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.

Learn more about medication use in pregnancy and postpartum, including risks and benefit analysis.

MRI-guided SAINT TMS aims to remit treatment-resistant depression in days.

Studies link compassion and wisdom to less loneliness and richer gut microbiome diversity, pointing to gut–brain targets for mental health interventions.

Guidance on psychotropic meds in pregnancy: personalize decisions, coordinate care, and plan early to prevent postpartum relapse.

Planning for prevention of perinatal psychiatric relapse with safer medication options.

Discover APA sessions on OCD therapies, gut-brain microbiome insights, AI, sports psychiatry, and geriatric updates from top clinicians.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.